Emily obtained her master's degree in Biomedical Sciences with a specialization in Clinical Epidemiology in 2020. After that, she worked at the PHARMO Institute for Drug Outcomes Research as a researcher, where she was involved in the development of research protocols, data management, statistical analysis, and methodology development.
In 2022, Emily started her PhD at the Netherlands Cancer Institute, focusing on the pre-diagnostic trajectory of sarcoma patients. Her research examines the impact of a prolonged diagnostic process on quality of life and survival within a large prospective cohort study called the QUEST study, which includes sarcoma patients from the Netherlands, the United Kingdom, Australia, and New Zealand. Additionally, she is actively involved in the EORTC Quality of Life Group, where she is working on a project related to patient involvement.